ATE193652T1 - Rapamycin formulierung zur iv-injektion - Google Patents

Rapamycin formulierung zur iv-injektion

Info

Publication number
ATE193652T1
ATE193652T1 AT93908637T AT93908637T ATE193652T1 AT E193652 T1 ATE193652 T1 AT E193652T1 AT 93908637 T AT93908637 T AT 93908637T AT 93908637 T AT93908637 T AT 93908637T AT E193652 T1 ATE193652 T1 AT E193652T1
Authority
AT
Austria
Prior art keywords
rapamycin
solution
weight percent
polyethylene glycol
percent
Prior art date
Application number
AT93908637T
Other languages
English (en)
Inventor
Robert Paul Waranis
Maureen Murphy Harrison
Thomas Waymond Leonard
Robin Peter Enever
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Application granted granted Critical
Publication of ATE193652T1 publication Critical patent/ATE193652T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT93908637T 1992-03-30 1993-03-29 Rapamycin formulierung zur iv-injektion ATE193652T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86053092A 1992-03-30 1992-03-30
PCT/US1993/002907 WO1993019763A1 (en) 1992-03-30 1993-03-29 Rapamycin formulation for iv injection

Publications (1)

Publication Number Publication Date
ATE193652T1 true ATE193652T1 (de) 2000-06-15

Family

ID=25333426

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93908637T ATE193652T1 (de) 1992-03-30 1993-03-29 Rapamycin formulierung zur iv-injektion

Country Status (21)

Country Link
US (1) US5530006A (de)
EP (1) EP0633783B1 (de)
JP (1) JPH07505628A (de)
KR (1) KR950700750A (de)
AT (1) ATE193652T1 (de)
AU (1) AU681579B2 (de)
CA (1) CA2132636C (de)
DE (1) DE69328829T2 (de)
DK (1) DK0633783T3 (de)
ES (1) ES2148224T3 (de)
GR (1) GR3034293T3 (de)
HU (2) HUT70947A (de)
LV (1) LV12657B (de)
MX (1) MX9301740A (de)
NZ (1) NZ251628A (de)
PH (1) PH30923A (de)
PT (1) PT633783E (de)
SG (1) SG49652A1 (de)
TW (1) TW427903B (de)
WO (1) WO1993019763A1 (de)
ZA (1) ZA932224B (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616588A (en) * 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
IL111003A0 (en) * 1993-09-30 1994-11-28 American Home Prod Multi-component oral rapamycin formulation
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
JP4105761B2 (ja) * 1993-11-19 2008-06-25 アボット・ラボラトリーズ ラパミシン（マクロライド）の半合成類似体免疫調節剤
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
DE69627992T2 (de) * 1996-01-08 2004-05-19 Kabushiki Kaisha Toshiba, Kawasaki Informationsaufzeichnungsmedium, aufzeichnungsverfahren und wiedergabegerät
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
US6682758B1 (en) 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
AU2001249182A1 (en) * 2000-03-14 2001-09-24 Genetics Institute Inc. Use of rapamycin and agents that inhibit b7 activity in immunomodulation
WO2001068134A2 (en) * 2000-03-14 2001-09-20 Genetics Institute, Inc. Therapies that improve graft survival, using antibodies against a b7 antigen
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
DK1319008T3 (da) 2000-09-19 2009-02-09 Wyeth Corp Vandoplöselige rapamycinestere
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
IL162734A0 (en) 2002-02-01 2005-11-20 Ariad Gene Therapeutics Inc Phosphorus-containing compounds & uses thereof
RU2344821C2 (ru) * 2002-07-30 2009-01-27 Уайт Парентеральные композиции, содержащие гидроксиэфиры рапамицина
WO2004027027A2 (en) 2002-09-18 2004-04-01 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
CN1882338A (zh) * 2003-09-18 2006-12-20 马库赛特公司 经巩膜递送
FR2862872A1 (fr) * 2003-12-02 2005-06-03 Palbian Snc Composition a l'etat aqueux pour l'application perfusable d'un principe actif, notamment pharmacologique tel que le paracetamol.
US20050220835A1 (en) * 2004-03-30 2005-10-06 Jayaraman Ramesh B Agent eluting bioimplantable devices and polymer systems for their preparation
US8003122B2 (en) 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7846940B2 (en) * 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US20060258698A1 (en) * 2005-02-09 2006-11-16 Sreenivasu Mudumba Liquid formulations for treatment of diseases or conditions
WO2006110601A2 (en) * 2005-04-07 2006-10-19 Nitromed, Inc. The genetic risk assessment in heart failure: impact of the genetic variation of nos3
AU2006299382A1 (en) * 2005-10-04 2007-04-12 Nitromed, Inc. The genetic risk assessment in heart failure: impact of genetic variation of beta 1 adrenergic receptor Gly389Arg polymorphism
CA2624933A1 (en) * 2005-10-04 2007-04-12 Nitromed, Inc. Methods for treating respiratory disorders
US8492400B2 (en) 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
WO2007097951A2 (en) * 2006-02-17 2007-08-30 Nitromed, Inc. Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
JP5506378B2 (ja) 2006-03-23 2014-05-28 参天製薬株式会社 血管透過性に関連する疾患または病気のための製剤および方法
US20090306027A1 (en) * 2006-04-10 2009-12-10 Nitomed, Inc. Genetic risk assessment in heart failure: impact of the genetic variation of g-protein beta 3 subunit polymorphism
US20080138405A1 (en) * 2006-12-06 2008-06-12 Raheja Praveen Sirolimus nanodispersion
US8440185B2 (en) * 2006-12-26 2013-05-14 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
WO2008083239A2 (en) * 2006-12-27 2008-07-10 The Johns Hopkins University Compositions and methods for stimulating an immune response
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US20100098770A1 (en) * 2008-10-16 2010-04-22 Manikandan Ramalingam Sirolimus pharmaceutical formulations
AU2010286361A1 (en) 2009-08-31 2012-03-15 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
KR101267813B1 (ko) * 2009-12-30 2013-06-04 주식회사 삼양바이오팜 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물
WO2011135580A2 (en) 2010-04-28 2011-11-03 Cadila Healthcare Limited Pharmaceutical compositions of sirolimus
US20120172796A1 (en) * 2010-12-30 2012-07-05 Chappa Ralph A Composition for intravascular delivery of therapeutic composition
US9603800B2 (en) 2012-04-12 2017-03-28 Yale University Methods of treating inflammatory and autoimmune diseases and disorders using nanolipogels
KR20150100716A (ko) 2012-12-19 2015-09-02 앰플리뮨, 인크. 항 인간 b7-h4 항체 및 이의 용도
EP2997373A1 (de) 2013-05-17 2016-03-23 MedImmune, LLC Rezeptoren für b7-h4
EP3212194A4 (de) 2014-10-29 2018-06-20 University Of Maryland Verfahren zur behandlung altersbedingter symptome bei säugetieren und zusammensetzungen dafür
CN108351687B (zh) 2015-09-04 2022-01-07 耶鲁大学 靶向胰腺和结肠的聚合胆汁酸纳米组合物
US20190117799A1 (en) 2016-04-01 2019-04-25 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
CN109789197A (zh) 2016-08-03 2019-05-21 奈斯科尔公司 用于调节lair信号转导的组合物和方法
EP4360714A3 (de) 2016-09-21 2024-07-24 Nextcure, Inc. Antikörper für siglec-15 und verfahren zur verwendung davon
JP7069177B2 (ja) 2016-09-21 2022-05-17 ネクストキュア インコーポレイテッド シグレック－１５に対する抗体及びその使用方法
WO2019217661A1 (en) 2018-05-09 2019-11-14 Yale University Compositions and systems for ex vivo cell modulation and methods of use thereof
CA3103661A1 (en) 2018-05-09 2019-11-14 Yale University Particles for spatiotemporal release of agents
KR20210143718A (ko) 2019-01-17 2021-11-29 조지아 테크 리서치 코포레이션 산화된 콜레스테롤을 함유하는 약물 전달 시스템
CN116600789A (zh) 2020-06-19 2023-08-15 耶鲁大学 用于诱导耐受性的聚合胆汁酸酯纳米颗粒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3627886A (en) * 1968-04-15 1971-12-14 Hoffmann La Roche Methods of solubilizing coumermycin employing urea, dimethylacetamide or mixtures thereof
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
US4707470A (en) * 1985-05-17 1987-11-17 Smithkline Beckman Corporation Polyene antibiotic emulsion formulation
US5202241A (en) * 1988-09-09 1993-04-13 Gruppo Lepetit S.P.A. Antibiotic GE 2270
KR0177158B1 (ko) * 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제

Also Published As

Publication number Publication date
ZA932224B (en) 1994-09-29
EP0633783A1 (de) 1995-01-18
LV12657B (lv) 2001-09-20
ES2148224T3 (es) 2000-10-16
DE69328829T2 (de) 2000-10-12
US5530006A (en) 1996-06-25
LV12657A (lv) 2001-05-20
EP0633783B1 (de) 2000-06-07
CA2132636C (en) 2002-12-17
CA2132636A1 (en) 1993-10-14
DK0633783T3 (da) 2000-09-25
PT633783E (pt) 2000-11-30
KR950700750A (ko) 1995-02-20
HU211841A9 (en) 1995-12-28
HU9402821D0 (en) 1994-12-28
AU681579B2 (en) 1997-09-04
MX9301740A (es) 1993-09-01
JPH07505628A (ja) 1995-06-22
GR3034293T3 (en) 2000-12-29
WO1993019763A1 (en) 1993-10-14
NZ251628A (en) 1996-07-26
DE69328829D1 (de) 2000-07-13
SG49652A1 (en) 1998-06-15
PH30923A (en) 1997-12-23
TW427903B (en) 2001-04-01
AU3939193A (en) 1993-11-08
HUT70947A (en) 1995-11-28

Similar Documents

Publication Publication Date Title
DE69328829D1 (de) Rapamycin formulierung zur iv-injektion
FI944536A0 (fi) Rapamysiiniformulaatio iv-injektiota varten
FI944537A (fi) Rapamysiinikoostumus i.v.-ruiskeeksi
LV10907A (lv) Interferona polietilenglikola atvasinajums
EA200200431A1 (ru) Фармацевтические композиции, обеспечивающие повышенные концентрации лекарства
ATE220920T1 (de) Stickstoffoxydabgebendes präparat zur reduzierung der toxizität von wirkstoffen
ES2171444T3 (es) Una solucion intravenosa que disminuye las perdidas de proteinas y de agua corporales.
PE20000018A1 (es) Composiciones farmaceuticas a base de dalfopristina y de quinupristina y su preparacion
ES2151255T3 (es) Poliaminoacido para fomentar la absorcion de insecticida.
DE69016087D1 (de) Stabile Lösungen von Rebeccamycinderivaten sowie deren Herstellung.
MX9301116A (es) Derivados de dioxolano.
KR900000081A (ko) 트리암테렌의 약학적 액제

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee